Enfortumab Vedotin for Advanced Urothelial Carcinoma With Peter H. O'Donnell, MD

The FDA recently approved enfortumab vedotin (Padcev®, Astellas Pharma US, Inc.) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after treatment with platinum-based chemotherapy and anti–programmed cell death protein 1 (anti–PD-1) or anti–programmed death ligand 1 (anti–PD-L1) therapy. The approval was based on EV-201, a phase 2 trial in which enfortumab vedotin produced a high rate of response in patients with locally advanced or m...
Continue reading

Pembrolizumab Approval: Non-Muscle Invasive Bladder Cancer

The FDA has approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) carcinoma in situ, with or without papillary tumors. Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is indicated for patients who are ineligible for or have elected not to receive radical cystectomy and who do not respond to bacillus Calmette-Guérin (BCG) therapy.The approval was based on Keynote 057 (NCT02625961), a multicenter, single...
Continue reading

Testicular Cancer: Half the Chemotherapy, Same Efficacy

​One cycle of chemotherapy with bleomycin, etoposide, and cisplatin (BEP) works just as well as two cycles for the adjuvant treatment of high-risk, stage 1 nonseminomatous or combined germ cell tumors of the testis, report the investigators of a single-arm phase 3 study.Patients with testicular cancer, the most common cancer among American males between the ages of 15 and 35, often present with stage 1 disease. However, many nonseminomas and combined germ cell tumors of the testis have malignant...
Continue reading

Enfortumab Vedotin Approved for Urothelial Carcinoma

​The FDA has approved enfortumab vedotin (Padcev®, Astellas Pharma US, Inc.) for patients with locally advanced or metastatic urothelial carcinoma. Enfortumab vedotin is indicated for patients whose disease progressed after prior treatment with platinum-based chemotherapy and anti–programmed cell death protein 1 (anti–PD-1) or anti–programmed death ligand 1 (anti–PD-L1) therapy. Enfortumab vedotin targets Nectin-4, a cell adhesion molecule highly expressed in urothelial cancers, and is the first...
Continue reading

Does Marijuana Use Increase Cancer Risk?

Nearly half of adults have used marijuana at some point in their lives, and rates are increasing; among young adults, marijuana usage doubled from 10.5% in 2002 to 21.2% in 2014. Given this widespread usage, the question of marijuana-associated cancer risk is an important one, and it is the subject of a systematic review and meta-analysis now published in JAMA Network Open.Marijuana smoke and tobacco smoke share a number of carcinogens. In addition, tetrahydrocannabinol, marijuana's primary psyc...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.